Welcome to Skilled in the Art. I’m Law.com IP reporter Scott Graham. Here’s what’s crossing my desk this week:
- It’s the Battle of Big Pharma as Amgen, Sanofi and Regeneron return to the Federal Circuit to fight over ground rules for antibody patents, with Bristol-Myers Squibb, Merck, Eli Lilly and Pfizer along as amici.
- BlackBerry faces the first of two big hurdles to revive its messaging patent suit against Facebook and Snap.
- Vizzi overcomes Brizzi in the early round of a trademark dispute over hard seltzer drinks.
- CareDx organ transplant patents still eligible following extra judicial scrutiny.
Who’s Arguing—Back to the Biotech Future
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]